ALTERNATIVES TO RIFAMPICIN: PERSPECTIVE ON THE CHOICE OF STRONG CYP3A INDUCERS FOR CONDUCTING CLINICAL DRUG-DRUG INTERACTION STUDIES.J. Bolleddula, S. Gopalakrishnan, P. Hu, J. Dong,K. VenkatakrishnanCLINICAL PHARMACOLOGY & THERAPEUTICS（2022）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
